Proliferation is the strongest prognosticator in node-negative breast cancer: Significance, error sources, alternatives and comparison with molecular prognostic markers

Breast Cancer Research and Treatment

Volumn 115, Issue 2, 2009, Pages 241-254

  Baak, Jan P A ^a,b,c   Gudlaugsson, Einar ^a,b   Skaland, Ivar ^a,b   Guo, Lydia Hui Ru ^d   Klos, Jan ^a   Lende, Tone Hoel ^a   Søiland, Håvard ^a   Janssen, Emiel A M ^a   Zur Hausen, Axel ^e  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Breast cancer; Error sources; Mitotic activity index; Molecular markers; Prognosis; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B; HISTONE H3; PHOSPHOHISTONE H3; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

ADULT; AGED; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; ERROR; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MITOSIS RATE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VALIDATION STUDY;

AGE FACTORS; AGED; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; MIDDLE AGED; MITOTIC INDEX; PROGNOSIS; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 67349148275     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0126-y     Document Type: Review

References (103)

1. A Goldhirsch WC Wood RD Gelber AS Coates B Thürlimann HJ Senn 2003 Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 21 3357 3365 10.1200/JCO.2003.04.576
2. Early Breast Cancer Trialists' Collaborative Group (EBCTG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0
3. Adjuvant! Online, at http://www.adjuvantonline.com
4. J Boyages B Chua R Taylor 2002 Use of the St. Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy Br J Surg 89 789 796 10.1046/j.1365-2168.2002.02113.x
5. JP Baak PJ van Diest FJ Voorhorst E van der Wall LV Beex JB Vermorken 2007 The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent Eur J Cancer 43 3 527 535 10.1016/j.ejca.2006.10.001
6. JP Baak EC Wisse-Brekelmans PH Kurver LH van Gorp FJ Voorhorst OS Miettinen 1992 Regional differences in breast cancer survival are correlated with differences in differentiation and rate of proliferation Hum Pathol 23 9 989 992 10.1016/0046-8177(92)90259-6
7. A Volpi F De Paola O Nanni AM Granato P Bajorko A Becciolini 2000 Prognostic significance of biologic markers in node-negative breast cancer patients, a prospective study Breast Cancer Res Treat 63 181 192 10.1023/A:1006464426977
8. C Desmedt C Sotiriou 2006 Proliferation: the most prominent predictor of clinical outcome in breast cancer Cell Cycle 19 2198 2202
9. JP Baak PJ van Diest FJ Voorhorst E van der Wall LV Beex JB Vermorken 2005 Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years J Clin Oncol 23 25 5993 6001 10.1200/JCO.2005.05.511
10. PJ Van Diest JPA Baak P Matze-Cok EC Wisse-Brekelmans CM van Galen PH Kurver 1992 Reproducibility of mitosis counting in 2469 breast cancer specimens, results from the multicentre morphometric mammary carcinoma project Hum Pathol 23 603 607 10.1016/0046-8177(92)90313-R
11. EAM Janssen PJ van Diest H Søiland E Gudlaugson A Nysted FJ Voorhorst 2006 Success factors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years Cell Oncol 28 5-6 295 303
12. D Amadori O Nanni M Marangolo P Pacini A Ravaioli A Rossi 2000 Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study J Clin Oncol 18 3125 3134
13. WE Fiets FE Bellot H Struikmans MA Blankenstein JW Nortier 2005 Prognostic value of mitotic counts in axillary node negative breast cancer patients with predominantly well-differentiated tumours Eur J Surg Oncol 31 2 128 133 10.1016/j.ejso.2004.08.012
14. PJ Westenend CJ Meurs RA Damhuis 2005 Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis J Clin Pathol 58 2 196 201 10.1136/jcp.2004.018515
15. PA Hall JJ Going 1999 Predicting the future, a critical appraisal of cancer prognosis studies Histopathology 35 489 494 10.1046/j.1365-2559.1999. 00862.x
16. JP Baak 2002 The framework of pathology, good laboratory practice by quantitative and molecular methods J Pathol 198 3 277 283 10.1002/path.1233
17. JP Baak PJ van Diest AT Ariens MW van Beek SM Bellot J Fijnheer 1989 The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands Pathol Res Pract 185 5 664 670
18. WS Bullough 1950 Mitotic activity of the tissue in dead mice, and in tissues kept in physiological salt solutions Exp Cell Res 1 410 420 10.1016/0014-4827(50)90019-X
19. N Graem K Helweg-Larsen 1979 Mitotic activity and delay in fixation of tumour tissue. The influence of delay in fixation on mitotic activity of a human osteogenic sarcoma grown in athymic nude mice Acta Pathol Microbiol Scand [A] 87A 5 375 378
20. K Donhuijsen U Schmidt H Hirsche D van Beuningen V Budach 1990 Changes in mitotic rate and cell cycle fractions caused by delay in fixation Hum Pathol 21 709 714 10.1016/0046-8177(90)90030-9
21. E Bergers I Jannink PJ van Diest MA Cuesta S Meyer JC van Mourik 1997 Influence of fixation delay on mitotic activity and flow cytometric %S-phase Hum Pathol 28 95 100 10.1016/S0046-8177(97)90286-0
22. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z et al (2008) Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma. J Clin Oncol 26(19):3153-3158
23. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V et al (2003) Invasive breast carcinoma. In: Tavassoli FA, Devilee P (eds) Pathology and genetics of tumours of the breast and female genital tract organs. IARC Press, Lyon, pp 18-19
24. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer, experience from a large study with long-term follow-up Histopathology 19 403 410 10.1111/j.1365-2559. 1991.tb00229.x
25. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, et al (2007) other collaborators of the Multicenter Morphometric Mammary Carcinoma Project (MMMCP). The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer 43(3):527-535. doi: 10.1016/j.ejca.2006.10.001
26. S Eppenberger-Castori DH Moore Jr AD Thor SM Edgerton W Kueng U Eppenberger 2002 Age-associated biomarker profiles of human breast cancer Int J Biochem Cell Biol 34 1318 1330 10.1016/S1357-2725(02)00052-3
27. JP Baak PJ van Diest EA Janssen E Gudlaugsson FJ Voorhorst E van der Wall 2008 Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers Ann Oncol 19 4 649 654 10.1093/annonc/mdm535
28. RB Greenough 1925 Varying degrees of malignancy in cancer of the breast J Cancer Res 9 425 463
29. HJG Bloom WW Richardson 1957 Histological grading and prognosis in breast cancer Br J Cancer 11 359 377
30. MM Black SR Opler FD Speer 1955 Survival in breast cancer cases in relation to the structure of the primary tumour and regional lymph nodes Surg Gynecol Obstet 100 5 543 551
31. Fisher ER (1986) Prognostic and therapeutic significance of pathological features of breast cancer. NCI Monogr (1):29-34
32. I Skaland PJ van Diest EAM Janssen E Gudlaugsson JPA Baak 2008 Prognostic differences of WHO-assessed mitotic activity index (MAI) and mitotic impression by quick scanning in invasive ductal breast cancer patients under 55 years of age Hum Pathol 39 4 584 590 10.1016/j.humpath.2007.08.016
33. I Jannink PJ van Diest JPA Baak 1996 Comparison of the prognostic value of mitotic frequency and mitotic activity index in breast cancer Breast 5 31 36 10.1016/S0960-9776(96)90046-6
34. I Jannink PJ van Diest JPA Baak 1995 Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium Hum Pathol 26 1086 1092 10.1016/0046-8177(95) 90270-8
35. SB Wharton KK Chan JR Anderson K Stoeber GH Williams 2001 Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labeling index, histological grade and prognosis Neuropathol Appl Neurobiol 27 305 313 10.1046/j.0305-1846.2001.00333.x
36. SB Wharton S Hibberd KL Eward D Crimmings DA Jellinek D Levy 2004 DNA replication licensing and cell cycle kinetics of oligodendroglial tumours Br J Cancer 91 262 269
37. IS Scott LS Morris K Bird RJ Davies SL Vowler SM Rushbrook 2003 A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer J Pathol 201 187 197 10.1002/path.1444
38. T Yoshida S Tanaka A Mogi Y Shitara H Kuwano 2004 The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer Ann Oncol 15 2 252 256 10.1093/annonc/mdh073
39. TJ Dudderidge K Stoeber M Loddo G Atkinson T Fanshawe DF Griffiths 2005 Mcm2, geminin and Ki67 define proliferative state and are prognostic markers in renal cell carcinoma Clin Cancer Res 11 2510 2517 10.1158/1078-0432.CCR-04-1776
40. A Shetty M Loddo T Fanshawe AT Prevost R Sainsbury GH Williams 2005 DNA replication licensing and cell cycle kinetics of normal and neoplastic breast Br J Cancer 93 1295 1300 10.1038/sj.bjc.6602829
41. EC Obermann KL Eward A Dogan EA Paul M Loddo P Munson 2005 DNA replication licensing in peripheral B-cell lymphoma J Pathol 205 318 328 10.1002/path.1695
42. PJ van Diest E van der Wall JP Baak 2004 Prognostic value of proliferation in invasive breast cancer, a review J Clin Pathol 57 7 675 681 10.1136/jcp. 2003.010777
43. I Skaland EA Janssen E Gudlaugsson J Klos KH Kjellevold H Søiland 2007 Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age Mod Pathol 20 12 1307 1315 10.1038/modpathol.3800972
44. RM Brenner OD Slayden WH Rodgers 2003 Immunohistochemical assessment of mitotic activity with an antibody to phosphorylated histone PPH3 in the macaque and human endometrium Hum Reprod 18 1185 1193 10.1093/humrep/deg255
45. G Juan F Traganos Z Darzynkiewicz 1999 Histone PPH3 phosphorylation in human monocytes and during HL-60 cell differentiation Exp Cell Res 246 212 220 10.1006/excr.1998.4283
46. C Bossard A Jarry C Colombeix 2006 PPH3-based a phosphohistone PPH3 labelling for histoprognostic grading of breast adenocarcinomas and computerassisted determination of mitotic index J Clin Pathol 59 706 710 10.1136/jcp. 2005.030452
47. Skaland I, Janssen EAM, Gudlaugsson E, Klos J, Kjellevold KH, Søiland S, Baak JPA (2008) Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res Treat. 10.1007/s10549-008-9980-x
48. P Rudolph H Kühling P Alm M Fernö B Baldetorp H Olsson 2003 Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer Int J Cancer 105 5 674 680 10.1002/ijc.11132
49. ZE Winters NC Hunt MJ Bradburn JA Royds H Turley AL Harris 2001 Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer and association with prognosis Eur J Cancer 37 2405 2412 10.1016/S0959-8049(01) 00327-6
50. T Suzuki T Urano Y Miki T Moriya J Akahira T Ishida 2007 Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor Cancer Sci 98 644 651 10.1111/j.1349-7006.2007.00444.x
51. MA Gonzalez KK Tachibana S-F Chin G Callagy M Madine SL Vowler 2004 Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression J Pathol 204 121 130 10.1002/path.1625
52. MA Gonzalez SE Pinder G Callagy SL Vowler LS Morris K Bird 2003 Minichromosome maintenance protein 2 is strong independent prognostic marker in breast cancer J Clin Oncol 21 4306 4313 10.1200/JCO.2003.04.121
53. E Björck S Ek O Landgren M Jerkeman M Ehinger M Björkholm 2005 High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma Blood 105 2908 2915 10.1182/blood-2004-07-2721
54. V Vuaroqueaux P Urban M Labuhn M Delorenzi P Wirapati CC Benz 2007 Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome Breast Cancer Res 9 3 R33 10.1186/bcr1681
55. F Janicke A Prechtl C Thomssen N Harbeck C Meisner M Untch 2001 Randomized adjuvant chemotherapy trial in high-risk, lymph nodenegative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 J Natl Cancer Inst 93 913 920 10.1093/jnci/93.12.913
56. M Look W van Putten M Duffy N Harbeck IJ Christensen C Thomssen 2003 Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients Thromb Haemost 90 538 548
57. I Zemzoum RE Kates JS Ross P Dettmar M Dutta C Henrichs 2003 Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer J Clin Oncol 21 1022 1028 10.1200/JCO.2003.04.170
58. B Cady 1997 New era in breast cancer. Impact of screening on disease presentation Surg Oncol Clin N Am 6 195 202
59. B Han M Nakamura I Mori Y Nakamura K Kakudo 2005 Urokinase type plasminogen activator system and breast cancer Oncol Rep 14 105 112 Review
60. P Leissner T Verjat T Bachelot M Paye A Krause A Puisieux 2006 Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer BMC Cancer 6 216 10.1186/1471-2407-6-216
61. P Urban V Vuaroqueaux M Labuhn M Delorenzi P Wirapati E Wight 2006 Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer J Clin Oncol 24 26 4245 4253 10.1200/JCO.2005.05.1912
62. CM Perou T Sørlie MB Eisen M van de Rijn SS Jeffrey CA Rees 2000 Molecular protraits of human breast tumours Nature 406 747 752 10.1038/35021093
63. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 10.1073/pnas. 191367098
64. C Fan DS Oh L Wessels B Weigelt DS Nuyten AB Nobel 2006 Concordance among gene-expression-based predictors for breast cancer N Engl J Med 355 6 560 569 10.1056/NEJMoa052933
65. SN Farrow R Brown 1996 New members of the Bcl-2 family and their protein partners Curr Opin Genet Dev 6 45 49 10.1016/S0959-437X(96)90009-X
66. E Yang SJ Korsmeyer 1996 Molecular thanatopsis: a discourse on the Bcl-2 family and cell death Blood 88 386 401
67. L J Biol Chem 271 6306 6312 10.1074/jbc.271.11.6306
68. T Miyashita S Kitada S Krajewski WA Horne D Delia JC Reed 1995 Overexpression of Bcl-2 protein increases the half-life of p21 (Bax) J Biol Chem 270 26049 26052 10.1074/jbc.270.44.26049
69. C Doglioni AP Dei Tos L Laurino C Chiarelli M Barbareschi 1994 The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlations, with particular reference to estrogen receptor status Virchows Arch 424 47 51 10.1007/BF00197392
70. S Krajewski M Krajewska A Shabaik T Miyashita HG Wang JC Reed 1994 Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2 Am J Pathol 145 1323 1336
71. S Krajewski C Blomqvist K Franssila M Krajewska VM Wasenius E Niskanen 1995 Reduced expression of the proapoptotic gene BAX is associated with poor response rates to combined chemotherapy and shortened survival in women with metastatic breast adenocarcinoma Cancer Res 55 4471 4478
72. M Barbareschi O Caffo S Veronese RD Leek P Fina S Fox 1996 Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up Hum Pathol 27 1149 1155 10.1016/S0046-8177(96)90307-X
73. RC Bargou PT Dainel MY Mapara K Bommert C Wagener B Killinich 1995 Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis Int J Cancer 60 854 859 10.1002/ijc.2910600622
74. N Kapucuoglu L Losi V Eusebi 1997 Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive breast carcinomas Virchows Arch 430 17 22 10.1007/BF01008011
75. 1 ductal breast carcinomas Int J Cancer 79 103 110 10.1002/(SICI)1097-0215(19980417)79:2<103::AID-IJC1>3.0.CO;2-X
76. S Veronese FA Mauri O Caffo M Scaioli D Aldovini G Perrone 1998 Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up Int J Cancer 79 13 18 10.1002/(SICI)1097-0215(19980220)79:1<13:: AID-IJC3>3.0.CO;2-Z
77. HJ van Slooten MJ van de Vijver CJ van de Velde JH van Dierendonck 1998 Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferation activity Br J Cancer 77 789 796
78. JS de Jong PJ van Diest JPA Baak 2000 Number of apoptotic cells as a prognostic marker in invasive breast cancer Br J Cancer 82 368 373 10.1054/bjoc.1999.0928
79. G Gasparini 1996 Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vincenza studies Eur J Cancer 32A 2485 2493 10.1016/S0959- 8049(96)00376-0
80. PB Vermeulen G Gasparini SB Fox M Toi L Martin P McCulloch 1996 Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation Eur J Cancer 32A 2472 2484
81. N Weidner JP Semple WR Welch J Folkman 1991 Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma N Engl J Med 324 1 8
82. JS de Jong PJ van Diest JPA Baak 2000 Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer Histopathology 36 306 312 10.1046/j.1365-2559.2000.00850. x
83. IM Stefansson HB Salvesen LA Akslen 2006 Vascular proliferation is important for clinical progress of endometrial cancer Cancer Res 66 6 3303 3309 10.1158/0008-5472.CAN-05-1163
84. I Papadopoulos A Giatromanolaki MI Koukourakis E Sivridis 2004 Tumour angiogenic activity and vascular survival ability in bladder carcinoma J Clin Pathol 57 3 250 255 10.1136/jcp. 2003.012005
85. A Goldhirsch JH Glick RD Gelber AS Coates B Thurlimann HJ Senn 2005 Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 1569 1583 10.1093/annonc/mdi326
86. V Marinho K Metze F Sanches G Rocha H Gobbi 2008 Lymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosis BMC Cancer 8 64 10.1186/1471-2407-8-64
87. Søiland H, Skaland I, Van Diermen B, Janssen E, Körner H, Varhaug JE et al (2007) Androgen receptor determination in breast cancer: a comparison of the dextran-coated charcoal method and quantitative immunohistochemical analysis. AIMM (Sep):19 (accepted for publication)
88. JT Rabban Y Chen 2008 D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma Hum Pathol 39 175 183 10.1016/j.humpath.2007.06.018
89. JS Reis-Filho PT Simpson T Gale SR Lakhani 2005 The molecular genetics of breast cancer: the contribution of comparative genomic hybridization Pathol Res Pract 201 11 713 725 10.1016/j.prp. 2005.05.013
90. A Kallioniemi OP Kallioniemi D Sudar D Rutovitz JW Gray F Waldman 1992 Comparative genomic hybridization for molecular cytogenetic analysis of solid tumours Science 258 818 821 10.1126/science.1359641
91. MM Weiss MA Hermsen GA Meijer NC van Grieken JP Baak EJ Kuipers 1999 Comparative genomic hybridisation Mol Pathol 52 5 243 251
92. EA Janssen JP Baak MA Guervós PJ van Diest M Jiwa MA Hermsen 2003 In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor J Pathol 201 4 555 561 10.1002/path.1475
93. C Sotiriou SY Neo LM McShane EL Korn PM Long A Jazaeri 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 18 10393 10398 10.1073/pnas.1732912100
94. Bertucci F, Orsetti B, Nègre V, Finetti P, Rougé C, Ahomadegbe JC et al (2008) Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene. [Epub ahead of print]
95. L Melchor E Honrado MJ García S Alvarez J Palacios A Osorio 2008 Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes Oncogene 27 22 3165 3175 10.1038/sj.onc.1210975
96. MJ van de Vijver YD He LJ van't Veer H Dai AA Hart DW Voskuil 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 1999 2009 10.1056/NEJMoa021967
97. Y Wang JG Klijn Y Zhang AM Sieuwerts MP Look F Yang 2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 9460 671 679
98. S Paik S Shak G Tang C Kim J Baker M Cronin 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817 2826 10.1056/NEJMoa041588
99. XJ Ma Z Wang PD Ryan SJ Isakoff A Barmettler A Fuller 2004 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell 5 6 607 616 10.1016/j.ccr.2004.05.015
100. M Buyse S Loi L van't Veer G Viale M Delorenzi AM Glas 2006 Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Nat Can Inst 98 1183 1192
101. A Goncalves B Esterni F Bertucci R Sauvan C Chabannon M Cubizolles 2006 Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy Oncogene 25 981 989 10.1038/sj.onc.1209131
102. G Ricolleau Charbonnel C Lode D Loussouarn MP Joalland R Bogumil 2006 Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors Proteomics 6 1963 1975
103. J Jacquemier C Ginestier J Rougemont VJ Bardou E Charafe-Jauffret J Geneix 2005 Protein expression profiling identifies subclasses of breast cancer and predicts prognosis Cancer Res 65 767 779